CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 60 target
Drug / intervention
DC cell Vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06477614
NCT06477614Phase 1RecruitingOn TrackUpdated 24mo ago
CompareCT.gov

Anti-cancer DC Cell Vaccination to Treat Advanced Solid Tumors: Phase I Clinical Trial

Second Affiliated Hospital of Guangzhou Medical University·interventional·Posted Jun 27, 2024·Updated Jun 27, 2024

In Brief

A Phase 1 clinical trial evaluating DC cell Vaccine for Solid Tumor, Adult and DC. Currently recruiting, targeting 60 participants across 1 site.

Detailed Summary

Placental or tumor-derived heat shock protein gp96 is collected, purified, and stored. The DC cells are isolated from the patient's blood and then cocultured with the gp96 to obtain the activated DC cell product. The manufactured DC cells are subcutaneously or intra-tumor injected into the patient. Clinical studies will be performed to test anti-cancer function of the DC vaccination for immunotherapy of cancer patients. In this phase I study, the safety, tolerance, and preliminary efficacy of the DC vaccine immunotherapy on advanced cancers will firstly be evaluated.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Adult, DC
CountriesChina
Collaborators--

Timeline

Phase 1Recruiting
202520262027202820292030203120322033203420352036
First PostedJun 27, 2024
Enrollment StartJun 5, 2024
Primary CompletionDec 30, 2030
Study CompletionDec 30, 2035
TodayJul 1, 2026
Enrollment to primary: 6.6 yearsPosted 2.0 years agoPrimary completion in 4.5 years

Interventions

DC cell Vaccinebiological

Deliver DC cell vaccine into patients for anti-ancer therapy.